Mechanistic evaluation of hyperoside against non-small cell lung cancer: a combined approach of network pharmacology and in vitro experimental validation
Hyp may be a promising drug for treating NSCLC (especially lung adenocarcinoma), and its therapeutic mechanisms is closely related to the regulation of EGFR/ERK/FOXO1 pathway.
Authors
- Yingchang Zou (ORCID: https://orcid.org/0000-0001-5253-8273)
- Haichao Zhan
- Lili Huang (ORCID: https://orcid.org/0000-0002-2857-6429)
- Zhaowei Zhang (ORCID: https://orcid.org/0000-0003-0997-5253)
- Liu Tang (ORCID: https://orcid.org/0000-0003-1599-7061)
- Guangwen Luo (ORCID: https://orcid.org/0000-0003-2683-1040)
- Shuang Xu
Institutions
- Wuhan University (CN)
- Ningbo Medical Center Lihuili Hospital (CN)
- Jinhua Academy of Agricultural Sciences (CN)
- Guang Fu Hospital (CN)
- Renmin Hospital of Wuhan University (CN)
- Jinhua Central Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1007/s12672-025-03622-9
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Zhejiang University